193 related articles for article (PubMed ID: 7910274)
1. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.
Connell WR; Kamm MA; Dickson M; Balkwill AM; Ritchie JK; Lennard-Jones JE
Lancet; 1994 May; 343(8908):1249-52. PubMed ID: 7910274
[TBL] [Abstract][Full Text] [Related]
2. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe.
Lakatos PL; Lovasz BD; David G; Pandur T; Erdelyi Z; Mester G; Balogh M; Szipocs I; Molnar C; Komaromi E; Golovics PA; Vegh Z; Mandel M; Horvath A; Szathmari M; Kiss LS; Lakatos L
J Crohns Colitis; 2013 Jun; 7(5):385-91. PubMed ID: 22766526
[TBL] [Abstract][Full Text] [Related]
3. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine.
Fraser AG; Orchard TR; Robinson EM; Jewell DP
Aliment Pharmacol Ther; 2002 Jul; 16(7):1225-32. PubMed ID: 12144571
[TBL] [Abstract][Full Text] [Related]
4. Azathioprine in the treatment of children with inflammatory bowel disease.
Verhave M; Winter HS; Grand RJ
J Pediatr; 1990 Nov; 117(5):809-14. PubMed ID: 2231216
[TBL] [Abstract][Full Text] [Related]
5. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
[TBL] [Abstract][Full Text] [Related]
6. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.
Korelitz BI; Mirsky FJ; Fleisher MR; Warman JI; Wisch N; Gleim GW
Am J Gastroenterol; 1999 Nov; 94(11):3248-53. PubMed ID: 10566724
[TBL] [Abstract][Full Text] [Related]
7. Use of azathioprine and the risk of cancer in inflammatory bowel disease.
Pasternak B; Svanström H; Schmiegelow K; Jess T; Hviid A
Am J Epidemiol; 2013 Jun; 177(11):1296-305. PubMed ID: 23514635
[TBL] [Abstract][Full Text] [Related]
8. Rectal lymphoma in ulcerative colitis treated with azathioprine.
Tan CW; Wilson GE; Howat JM; Shreeve DR
Eur J Gastroenterol Hepatol; 2001 Aug; 13(8):989-92. PubMed ID: 11507370
[TBL] [Abstract][Full Text] [Related]
9. Azathioprine therapy for inflammatory bowel disease. A preliminary report.
Brown CH; Achkar E
Am J Gastroenterol; 1970 Oct; 54(4):363-77. PubMed ID: 5478849
[No Abstract] [Full Text] [Related]
10. Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease.
Sultan K; Korelitz BI; Present D; Katz S; Sunday S; Shapira I
Inflamm Bowel Dis; 2012 Oct; 18(10):1855-8. PubMed ID: 22241664
[TBL] [Abstract][Full Text] [Related]
11. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study.
Armstrong RG; West J; Card TR
Am J Gastroenterol; 2010 Jul; 105(7):1604-9. PubMed ID: 20104215
[TBL] [Abstract][Full Text] [Related]
12. Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity.
Teich N; Mohl W; Bokemeyer B; Bündgens B; Büning J; Miehlke S; Hüppe D; Maaser C; Klugmann T; Kruis W; Siegmund B; Helwig U; Weismüller J; Drabik A; Stallmach A;
J Crohns Colitis; 2016 Jan; 10(1):61-8. PubMed ID: 26468141
[TBL] [Abstract][Full Text] [Related]
13. Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease.
Mossop H; Davies P; Murphy MS
J Pediatr Gastroenterol Nutr; 2008 Aug; 47(2):123-9. PubMed ID: 18664861
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Crohn disease in the Czech Republic in the years 1990 to 2001 and assessment of pediatric population with inflammatory bowel disease.
Pozler O; Maly J; Bonova O; Dedek P; Frühauf P; Havlickova A; Janatova T; Jimramovsky F; Klimova L; Klusacek D; Kocourkova D; Kolek A; Kotalova R; Marx D; Nevoral J; Petro R; Petru O; Plasilova I; Seidl Z; Sekyrova I; Semendak N; Schreierova I; Stanek J; Sykora J; Sulakova A; Toukalkova L; Travnickova R; Volf V; Zahradnicek L; Zenisková I
J Pediatr Gastroenterol Nutr; 2006 Feb; 42(2):186-9. PubMed ID: 16456413
[TBL] [Abstract][Full Text] [Related]
15. Management of varicella infection during the course of inflammatory bowel disease.
Mouzas IA; Greenstein AJ; Giannadaki E; Balasubramanian S; Manousos ON; Sachar DB
Am J Gastroenterol; 1997 Sep; 92(9):1534-7. PubMed ID: 9317080
[TBL] [Abstract][Full Text] [Related]
16. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
17. [Azathioprine in inflammatory bowel disease].
Leite S; Ribeiro JM; Lima SC; Barroso S; Cotter J
Acta Med Port; 2009; 22(1):33-40. PubMed ID: 19341591
[TBL] [Abstract][Full Text] [Related]
18. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
[TBL] [Abstract][Full Text] [Related]
19. Azathioprine dose escalation in inflammatory bowel disease.
Rayner CK; Hart AL; Hayward CM; Emmanuel AV; Kamm MA
Aliment Pharmacol Ther; 2004 Jul; 20(1):65-71. PubMed ID: 15225172
[TBL] [Abstract][Full Text] [Related]
20. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
